MEK inhibitor cobimetinib increases calreticulin and induces immune modulation in TNBC.

J Mol Med (Berl) · 2026 · PMC13201367 · PMID 42183887

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

However, further analysis of FOXP3 expression showed that the CD4 + CD25 + FOXP3 + population did not increase, but instead exhibited a decreasing trend without statistical significance (Supplementary Fig. 2 b).

also in 47,180 other papers

an increasing trendno p-value reported

The COLET study demonstrated an increasing trend in the overall response rate in patients with PD-L1-positive disease when treated with a combination of an anti-PD-L1 antibody, paclitaxel, and cobimetinib [ 20 ].

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.